To evaluate the biosynthetic basis for decreased glycoprotein (GP) Ib-IX expression resulting from GP IX mutations described in three siblings with Bernard-Soulier syndrome, we introduced each mutation into the cDNA for GP IX by site-directed mutagenesis (GP IX Asp,, -, Gly and GP IX Asna -, Ser) and examined the associations of the mutants with the two other subunits of .the GP Ib-IX complex in transfected cells. Unlike wild-type GP IX, neither of the mutants was able t o increase GP Ib expression on the cell surface, either when transfected into Chinese hamster ovary (CHO) up cells or when cotransfected with GP Iba and GP Ib@ into wild-type CH0 cells. We also evaluated whether cotransfecting wild-type or mutant GP IX with GP Ibp would result in the appearance of GP IX on the surface of the transfected cells; the wild-type protein was detected on the surface of the cells, whereas neither mutant reached the cell surface in appreciable quantities. Immunofluorescence ANY PROTEINS CONSIST of assemblies of more than one polypeptide, often requiring each component for their proper function. In some cases, each component may also be required for synthesis and stability of the polypeptide complex, so that mutations of any of the components could abrogate synthesis of a functional complex. The thalassemias provide a good example of this phenomenon. In these disorders, reduced or absent synthesis of a globin chain leads to failure to form adequate levels of hemoglobin tetramers (from two a-like and two p-like chains), resulting in instability of both the remaining globin chains and the cells in which they are synthesized.'
ANY PROTEINS CONSIST of assemblies of more than one polypeptide, often requiring each component for their proper function. In some cases, each component may also be required for synthesis and stability of the polypeptide complex, so that mutations of any of the components could abrogate synthesis of a functional complex. The thalassemias provide a good example of this phenomenon. In these disorders, reduced or absent synthesis of a globin chain leads to failure to form adequate levels of hemoglobin tetramers (from two a-like and two p-like chains), resulting in instability of both the remaining globin chains and the cells in which they are synthesized. ' The Bernard-Soulier syndrome (BSS) is another example of this type of disorder. In this hereditary bleeding diathesis, the platelets of affected persons do not adhere to regions of vascular damage and, therefore, also do not adequately seal injured blood vessels and prevent blood loss.' This disorder results from the dysfunction or absence of the platelet membrane receptor for von Willebrand factor (vWF), the glycoprotein (GP) Ib-IX-V complex. The GP Ib-IX-V complex, as its name implies, comprises several polypeptides: GP Iba, GP Ibo, GP IX, and GP V. Each polypeptide is produced from its own gene and joins the others during assembly of the complex to yield a surface receptor with a stoichiometry of 2:2:2:1 for GP Iba, GP Ibo, GP IX, and GP V, respectively.3 GP Iba contains the region that performs the most obvious (and possibly most important) function of the complex-binding V W F .~.~ The functional roles of the other polypeptides are poorly understood, although both GP Ibp and GP IX are needed to achieve adequate levels of GP Iba on the cell surface.' The role of GP V in surface expression is just now being studied. It is clear that several features of the complex can be reconstituted by expression of the cDNAs for GP Iba, GP IbP, and GP IX. This GP Ib-IX complex is expressed on cell surfaces and is capable of binding vWF and a number of conformation-sensitive antibodies. GP Ib (a and p)' and GP Iba by itself'j can also be expressed on the cell surface, but much less efficiently than in the presence of GP IX.
Recently, several mutations from BSS patients have been characterized that further illustrate the participation of the different chains in expression of a functional receptor on the cell surface. One mutation is of particular interest in this regard because it involves a polypeptide that does not directly participate in the ligand-binding function of the complex: GP IX. Wright et aI7 described a case of BSS that resulted from compound heterozygosity for GP IX mutations. The two mutations each involved single base changes that result in amino acid substitutions. Both changes occur in a conserved region that contains a structural leucine-rich motif that is also present in each of the polypeptides of the GP Ib-IX-V complex and in a large number of other proteins of varied functions and widespread distribution.3 The leucine-rich motif comprises one copy or tandem repeats of a 24-amino acid sequence and conserved sequences that flank the repeats on both the amino-terminal and the carboxylterminal sides. GP Iba contains seven tandem repeats of the central sequence, GP V contains 15 repeats, and GP Ibo and GP IX each contain one copy. One of the GP IX mutations, Asp2, --t Gly, occurs in the amino-terminal flanking sequence; the other, + Ser, involves an amino acid that is among the most highly conserved within the consensus sequence of the leucine-rich repeats3 (Fig 1) . Although these mutations were the only changes found in the GP IX gene QP IX Asp,, -Gly G from the affected kindred, the ultimate proof of their role in the disorder requires that the biosynthetic defect apparent in the platelets of these patients be reconstituted by expression of the mutant in vitro. This was the goal of the studies reported here.
MATERIALS AND METHODS
Cell lines. Two stable cell lines were used in the current studies; Antibodies. Polyclonal antiserum to GP IbP has been described.' Polyclonal antiserum to GP IX was a gift from Dr Gerald Roth, Seattle Veterans Affairs Medical Center (Seattle, WA). Monoclonal antibodies used were AN5 1 (IgG%) against GP Iba (DAKO, Carpinteria, CA) and FMC25 (IgG, , a gift from Dr Michael Bemdt of the Baker Research Institute, Prahran, Australia). Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG and goat anti-rabbit antibodies were purchased from Zymed, Inc, South San Francisco, CA.
Transfections. CH0 aPn cells were transiently transfected with GP IX plasmids, and C H 0 DUK-cells were transiently transfected with either the three GP Ib-IX complex polypeptides (GP Iba, GP Ibp, and wild-type or mutant GP IX) or only plasmids for GP IbP or GP IX (wild-type or mutant). Transfections were by lipofection, using a commercially available kit (LipofectAMINE; GIBCO B E ) . Cells were passed on the day before the transfections so as to reach approximately 80% confluence at the time of transfection. Eight microliters of liposome suspension and 1 pg of plasmid DNA were separately mixed in 100 pL of serum-free medium; the two suspensions were then combined, mixed gently, and allowed to incubate for 30 minutes at room temperature to form DNA-liposome complexes. The mixture was diluted in 0.8 mL of serum-free medium and added to cells in a 3 5 -m ' culture dish that had been washed twice in the same medium. The cells were exposed to the DNA/ liposome mixture for 5 hours under standard culture conditions (37°C. 5% COz), after which time an additional 1 mL of medium containing 10% FBS was added. The medium was changed 24 hours later. After 48 hours, the cells were detached from the dishes with 0.54 mmoVL of EDTA and were analyzed further.
Flow cytometty. Detached cells were labeled either with FITCconjugated monoclonal antibodies or with unlabeled primary antibodies followed by FITC-conjugated rabbit anti-mouse secondary antibodies. When a two-antibody sandwich was used to label the cells, they were first incubated in the primary antibody (5 pg/mL) for 30 minutes at room temperature, washed twice by resuspension in phosphate-buffered saline (PBS), incubated for 30 minutes in 5 pg/mL of FITC-labeled secondary antiserum, and washed twice again with PBS. To determine viability, the cells were then resuspended in PBS containing propidium iodide (PI; 20 pg/mL) before analysis.
To analyze the population of live cells, PI-positive cells were first gated out by stimulating the fluorophor at 488 nm and detecting at greater than 620 nm. Cells with fluorescence emission at greater than 620 nm that was 200-fold over background were excluded from further analysis. The cells were also gated based on the fonvardand side-scatter characteristics of a control parent CH0 cell population. At least 10, OOO gated cells from each transfection were then analyzed by exciting the FITC label at 480 nm using an argon ion laser and evaluating emission at 520 nm. The analyses were performed on a Becton Dickinson (San Jose, CA) FACStar flow cytometer.
Fluorescence microscopy. For these experiments, transfections were performed directly on two-well chamber slides (Titertek; Nunc, Naperville, IL), with the amount of DNA and liposome suspension adjusted based on the surface area of the chamber. At 48 to 72 hours after transfection, the cells were washed with PBS, fixed with 4% paraformaldehyde (Sigma) for 15 minutes, and permeabilized with 0.1% Triton X-100 (Sigma) for 15 minutes. The fluorescence of the fixative was quenched with several washes in 0.15 m o l L ammonium acetate. The cells were then incubated in 5 pg/mL of monoclonal antibody (FMC25) for 30 minutes, washed several times with PBS, and incubated in a 1:1,OOO dilution of FITC-conjugated rabbit anti-mouse secondary antibody for 30 minutes. After several washes with PBS, the cells were examined on a Zeiss fluorescence microscope (Carl Zeiss, Inc, Sanheandro, CA). Immunofluorescence studies were also performed using polyclonal anti-GP IX. In this case, Mutagenesis. The GP M cDNA was cloned into the mammalian expression vector pDX," in which all the mutagenesis reactions were performed. A commercially available kit (Transformer; Clontech, Palo Alto, CA) was used to perform mutagenesis using the method of Deng and Nickoloff." To mutate codon 21 from an Asp to a Gly codon, the following mutagenic primer corresponding to nucleotides 322 to 344 of the published sequences" was annealed to the plasmid containing the GP IX cDNA: CTG TGG GTG GgC TGC AGG GGC CA. To mutate codon 45 from Asp to Ser, the following oligonucleotide was used: CTG GTG GCC AAC AgC AGC CTT CAG TCC G. This primer, with the exception of the single nucleotide change, corresponds to nucleotides 391 to 418 of the GP IX cDNA. The cDNA insert of each of the mutant plasmids was sequenced in its entirety to verify the mutation and rule out unwanted mutations. The AB1 Dye terminator kit was used for sequencing, and the sequencing reactions were analyzed on an AB1 (Foster City, CA) model 373A automated sequencer.
Metabolic labeling and immunoprecipitation. CH0 DUK-cells transiently transfected with a GP IbP plasmid and wild-type or mutant GP IX plasmids in 50-cm2 cell-culture dishes were washed twice in cysteine-free a-MEM and then incubated in this medium for 1 hour before the addition of 0.1 mCi [35S]cysteine (ICN, Imine, CA). The cells were incubated in the radioactive medium for 4 hours, the medium was then removed, and the cells were washed twice in PBS. Radiolabeled cells were lysed in digitonin lysis buffer (100 mmol/ L Tris pH 7.4, 1 mg/mL leupeptin, 1.6 mg/mL benzamidine, 0.1 pg/mL soybean trypsin inhibitor, 1 mmol/L phenylmethylsulfonyl fluoride, and 1% digitonin) and centrifuged at 14,OOOg for 5 minutes to remove debris. The lysate was incubated overnight at 4°C with fixed Staphylococcus aureus cells (Pansorbin; Calbiochem, L a Jolla, CA) to remove proteins that bind the dead bacteria nonspecifically.
To immunoprecipitate GP IX, FMC25 (10 pg/mL) was added to the lysate, and the mixture was incubated for 4 hours. Pansorbin beads that had been preequilibrated with rabbit anti-mouse IgG ( 5 pg/mL, 4 hours) were then added to the lysate and incubated for 4 hours.
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To precipitate GP IbP, the cleared lysate was incubated with polyclonal GP IbP antiserum (10 pg/mL) for 4 hours, and the Pansorbin beads were then added directly to the lysate and incubated for an additional 4 hours. In both cases, bound protein was removed from the lysate by centrifugation at 14,OOOg for 5 minutes. The bead pellet was then washed several times in lysis buffer by resuspension and centrifugation. Immunoprecipitated proteins were removed from the beads by boiling in sodium dodecyl sulfate (SDS)-sample buffer" for 5 minutes. The proteins were then resolved on the basis of molecular mass by electrophoresis on 12.5% SDS-polyacrylamide gels. The radioactivity on the dried gels was determined by autoradiography using a Fuji phosphorimager (Model BASIW), and the results were analyzed with the Fuji (Stamford, CT) MACBAS software package.
RESULTS
Our previous studies have demonstrated that supertransfection of GP IX into cells that stably express GP Ib (a and p) can significantly increase the level of GP Ib on the cell surface, presumably by forming a complex that stabilizes GP Ib.' We examined whether either mutant GP IX (GP IX Asp,, + Gly and GP IX + Ser) or a combination of both could do the same. We chose to use a cell line in which expression of GP Ib was not amplified (CH0 &); only a small population of these cells actually express GP Ib on their surfaces (Fig 2) . CH0 a p n cells were transfected with plasmid (pDX) only (sham-transfected), with wild-type GP IX, or with the two GP IX mutants, alone or together. When labeled with the anti-GP Iba antibody AN51, shamtransfected CH0 a p n cells displayed two cell populations (Fig 2A) transfected with wild-type or mutant GP IX plasmids were not significantly different for cells in gate 2. However, compared with cells transfected with plasmid alone, the cells in gate 2 in the wild-type GP IX transfection displayed significantly greater levels of GP Iba on their surfaces (Fig 2B) . In contrast, neither of the two GP IX mutants, either alone or in combination, significantly increased GP Iba expression on the cell surface over the levels found on sham-transfected cells.
As another means of evaluating the role of the mutant GP IX polypeptides on surface expression of GP Ib, all three GP Ib-IX complex polypeptides were transiently expressed by cotransfection into C H 0 DUK-cells. Expression of GP Ib on the cell surface was again evaluated with AN5 1. Once again, GP Ib expression on the cell surface was greater when plasmids for GP Iba and GP IbP were cotransfected with wild-type GP IX than when they were cotransfected with either of the mutant GP IX plasmids or with both together (Fig 3) . The mean fluorescence of the cells containing wildtype GP IX (average from three experiments) was approximately twice that of the cells containing any of the mutants.
The results shown in Figs 2 and 3 indicate that the mutant GP IX polypeptides do not function like wild-type GP IX in increasing plasma membrane expression of GP Iba, possibly because they do not associate with GP Ib. We had demonstrated earlier that GP IX associates with GP Ib through a noncovalent association with GP Ibo' and demonstrated that the association of GP IX with GP Ibo increases GP IX expression on the cell surface. We therefore also tested whether the mutant GP IX polypeptide increased on the cell surface when transfected with GP IbP. In these experiments, expression of GP IX on the cell surface after transfection of the wild-type or mutant plasmid with GP IbP was compared with expression after transfection of wild-type GP IX by itself (Fig 4) . Expression of wild-type GP IX on the cell surface was considerably greater when it was cotransfected with GP IbP than when it was transfected alone (Fig 4A,  upper left panel) . In marked contrast, neither of the mutant GP IX polypeptides, either when each was transfected alone or when they were cotransfected with GP Ibp, were found on the cell surface at levels significantly higher than those of sham-transfected cells. Mean GP IX fluorescence in cells from these cotransfections did not differ from that of cells transfected with wild-type GP IX alone (Fig 48) .
One possibility for the observed dysfunction of the GP 1X mutants is that both mutations might result in synthetic defects of the mutant polypeptides. Alternatively, the mutants could be sequestered within intracellular compartments and not reach the cell surface or be targeted for early degradation. We investigated these possibilities by immunofluorescence microscopy of cells transiently cotransfected with GP IX (wild-type or mutant) and GP IbP after the cells were rendered permeable with 0.1 % Triton X-100. A polyclonal antiserum was used to detect GP IX. The wild-type polypeptide was detected at high levels within the intracellular compartments (Fig SB) . Each of the mutant polypeptides was also detected intracellularly ( Fig  SC and D) , but at lower levels than was wild-type GP IX. The GP IX Asp,, -+ Gly mutant was affected more severely ( Fig  X ) . In cells transfected with this mutant, only rare fluorescent cells were found, and those had much lower GP IX levels than did cells transfected with wild-type GP IX (Fig SC) .
This result clearly indicated that the most probably explanation for the failure of either GP IX mutant to augment GP Ib expression on the plasma membrane was its failure to associate noncovalently with GP IbP. Our previous studies have shown that antibodies against either polypeptide are capable of precipitating both polypeptides. ' A.
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tested directly the GP IX mutants associated with GP IbP by immunoprecipitating GP IbP from cells transiently coexpressing both polypeptides. In the cotransfections with either mutant polypeptide, the amount of GP IX associated with GP IbP was greatly diminished when compared with the amount of wild-type GP IX associated (Fig 6) . The relative ratios of GP IX to GP IbP were only 23% and 7% for GP IX Amd5 -+ Ser and GP IX Asp2, + Gly, respectively, as compared with wild-type GP IX. The amounts precipitated paralleled the levels found by microscopy in intracellular compartments.
DISCUSSION
BSS is an autosomal recessive bleeding disorder resulting from an absent or abnormal receptor for vWF on the surfaces of the platelets of affected patients. Because four polypeptides (GP Iba, GP IbP, GP M, and GP V) have been described as diminished or absent in platelets from different BSS patients,' and because each of the missing polypeptides is encoded by its own gene, the disorder could potentially be caused by homozygous or compound heterozygous mutations in any one of these genes. Thus far, cases of BSS with decreased levels of the GP Ib-IX-V polypeptide arising from mutations of GP IbaI4.', and GP IX7 have been described, but not cases arising from mutations of the genes encoding either of the other two polypeptides. Mutations of GP IbP also are likely to cause the disorder, particularly given the role of this polypeptide in synthesis of the c~m p l e x .~ Mutations of GP V might also cause BSS, but they appear less likely to do so, given that a functional receptor can be reconstituted in heterologous cells by transfecting only cDNAs for GP Iba, GP IbP, and GP IX.,
Mutations that diminish GP Iba synthesis cause BSS for obvious reasons: this polypeptide contains the regions that mediate complex binding to both vWF and thrombin. Neither of these functions apparently requires participation from either of the other polypeptides of the complex; interpretation of the functional defect is, therefore, straightforward. In cases of BSS due to mutations of GP IX, however, interpretation of the mechanism by which the mutation causes this disorder is not as obvious. Our studies in heterologous cells indicate that any mutation that interferes with synthesis of either GP IbP or GP IX might cause the disorder if these mutations decrease synthesis of the mutant polypeptide or if they lead to its instability or failure to associate with its co~nterpart.~.' This seems to be the mechanism by which the mutations studied in this report (originally described by Wright et a17 in three affected members of one family) cause BSS. We found that both mutant polypeptides (GP IX Asp,, -+ Gly and GP IX Asp,, -+ Ser) associated poorly with GP IbP.
Failure to associate with GP IbP prevents the mutants from performing what may be one of the more vital functions of GP IX-to stabilize GP Ib on the cell surface. This hypothesis is fully compatible with the observations of the platelet phenotype made by Wright et al. 7 They found no expression of GP IX in the platelets of the patients, either on the cell surface by flow cytometry or within the cells by immunoblotting of platelet lysates. (One caveat about these studies, which also applies to our studies shown in Fig 4, is that the FMC25 epitope may be destroyed by the mutations and, thus, not detect mutant polypeptide on the cell surface.) They did find, however, a subset of platelets with reduced but detectable levels of GP Ib on their surfaces, as determined by immunostaining with a monoclonal antibody against GP Iba. This platelet population may have represented younger platelets that were more recently released from the bone marrow. This observation from patient platelets clearly parallels observations in our laboratory, in this and a previous study, where although GP Ib alone appears on the surface and is completely processed, it is much less stable there than it is in the presence of GP IX.5
The finding that two GP IX molecules with mutations in different regions of the conserved leucine-rich motif both do not associate with GP IbP suggests a role for this conserved motif in the biology of the GP Ib-IX-V complex: this may be the region through which these two polypeptides associate with each other. The leucine-rich motif is present in a very large number of proteins and has been implicated in proteinprotein interactions.3 Particularly interesting among those interactions are the adhesion reactions mediated by three developmentally important Drosc~philr~ proteins: Toll. chaoptin, and connectin. Chaoptin and connectin appear to mediate homophilic aggregation of cells in which they are expressed by binding to identical receptors on other Toll is able to induce aggregation through a heterophilic mechanism.'x GP Ibp and GP IX, whose extracellular regions are very similar,' may interact with each other in an analogous manner. In this case, however, rather than recognizing an identical protein on the surface of another cell, they may bind to a very similar protein on the same cell. This hypothesis remains to be proved directly.
At least two possible mechanisms could account for failure of GP IX to associate with GP Ibp, one of which implies -30 kDa
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For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From nothing about the mechanism by which the polypeptides associate. First, the conformational alteration in GP IX could lead to its rapid degradation in the endoplasmic reticulum, or possibly such a change in conformation would first lead to its retention (possibly by binding BiP)19 and then its subsequent degradation. In this situation, the mutants might not associate with GP Ibo because they are degraded before the association can occur. That small fraction that does associate may be stabilized by the association. Alternatively, excess GP IX molecules (in excess of those needed to bind GP Ibp) under normal circumstances might be degraded fairly rapidly, and failure of the mutants to bind GP IbP could commit them to the same default degradation pathway. In this case, the failure to associate with GP IbP is the direct cause of the instability.
In either situation, the biosynthetic defects described in this report ascribe a very important function to the leucinerich motif of GP IX in maintaining the stability of the polypeptide. As more mutations from patients with BSS are described, more will be learned about the roles of the motif in the functions of all of the polypeptides of the GP Ib-IX-V complex.
